pd 1 protein human recombinant  (Sino Biological)


Bioz Verified Symbol Sino Biological is a verified supplier
Bioz Manufacturer Symbol Sino Biological manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 88
    Name:
    Human PD1 PDCD1 Protein His Fc Tag
    Description:
    A DNA sequence encoding the extracellular domain Met 1 Gln 167 of human PD1 NP 005009 2 was fused with the C terminal polyhistidine tagged Fc region of human IgG1 at the C terminus
    Catalog Number:
    10377-H03H
    Price:
    None
    Category:
    recombinant protein
    Host:
    HEK293 Cells
    Buy from Supplier


    Structured Review

    Sino Biological pd 1 protein human recombinant
    <t>PD-1/PD-L1</t> binding directly activates the intracellular AKT/mTOR oncogene signaling in DLBCL cells
    A DNA sequence encoding the extracellular domain Met 1 Gln 167 of human PD1 NP 005009 2 was fused with the C terminal polyhistidine tagged Fc region of human IgG1 at the C terminus
    https://www.bioz.com/result/pd 1 protein human recombinant/product/Sino Biological
    Average 88 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pd 1 protein human recombinant - by Bioz Stars, 2021-04
    88/100 stars

    Images

    1) Product Images from "Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells"

    Article Title: Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells

    Journal: Oncotarget

    doi: 10.18632/oncotarget.9061

    PD-1/PD-L1 binding directly activates the intracellular AKT/mTOR oncogene signaling in DLBCL cells
    Figure Legend Snippet: PD-1/PD-L1 binding directly activates the intracellular AKT/mTOR oncogene signaling in DLBCL cells

    Techniques Used: Binding Assay

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 88
    Sino Biological pd 1 protein human recombinant
    <t>PD-1/PD-L1</t> binding directly activates the intracellular AKT/mTOR oncogene signaling in DLBCL cells
    Pd 1 Protein Human Recombinant, supplied by Sino Biological, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/pd 1 protein human recombinant/product/Sino Biological
    Average 88 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    pd 1 protein human recombinant - by Bioz Stars, 2021-04
    88/100 stars
      Buy from Supplier

    94
    Sino Biological human pd 1 fc
    In vitro cell-based <t>PD-1/PD-L1</t> inhibition assay in comparison with primary scFv screenings. Evaluation of in vitro assays to assess the inhibition of PD-1‒PD-L1 interactions by full IgG antibodies. The activity of 40 full IgG converted antibodies in blocking the effect of the PD1/PD-L1 checkpoint on TCR-mediated T cell activation is assessed as the level of luciferase activity. MK3475 (anti-PD-1) and MPDL3280A (anti-PD-L1) antibodies were used as positive controls (green bar). The light blue bars have binding activity of antibody clones against human PD-L1 antigen, whereas yellow bars have cross-reactivity to both human and mouse PD-L1 antigens. Results are classified using color shading codes, with the top 30% in red and the bottom 30% in blue in each assay (scFvs 30%; 12/40 clones and 22/72 clones).
    Human Pd 1 Fc, supplied by Sino Biological, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human pd 1 fc/product/Sino Biological
    Average 94 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    human pd 1 fc - by Bioz Stars, 2021-04
    94/100 stars
      Buy from Supplier

    Image Search Results


    PD-1/PD-L1 binding directly activates the intracellular AKT/mTOR oncogene signaling in DLBCL cells

    Journal: Oncotarget

    Article Title: Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells

    doi: 10.18632/oncotarget.9061

    Figure Lengend Snippet: PD-1/PD-L1 binding directly activates the intracellular AKT/mTOR oncogene signaling in DLBCL cells

    Article Snippet: Stimulation of DLBCL-cell lines with human recombinant PD-1/FCAll five cell lines were cultured in complete medium containing 100ug/ml human recombinant PD1/Fc (10377-H03H, Sino Biological Inc., Beijing, China) for 24h and 48h.

    Techniques: Binding Assay

    In vitro cell-based PD-1/PD-L1 inhibition assay in comparison with primary scFv screenings. Evaluation of in vitro assays to assess the inhibition of PD-1‒PD-L1 interactions by full IgG antibodies. The activity of 40 full IgG converted antibodies in blocking the effect of the PD1/PD-L1 checkpoint on TCR-mediated T cell activation is assessed as the level of luciferase activity. MK3475 (anti-PD-1) and MPDL3280A (anti-PD-L1) antibodies were used as positive controls (green bar). The light blue bars have binding activity of antibody clones against human PD-L1 antigen, whereas yellow bars have cross-reactivity to both human and mouse PD-L1 antigens. Results are classified using color shading codes, with the top 30% in red and the bottom 30% in blue in each assay (scFvs 30%; 12/40 clones and 22/72 clones).

    Journal: Viruses

    Article Title: BLI-Based Functional Assay in Phage Display Benefits the Development of a PD-L1-Targeting Therapeutic Antibody

    doi: 10.3390/v12060684

    Figure Lengend Snippet: In vitro cell-based PD-1/PD-L1 inhibition assay in comparison with primary scFv screenings. Evaluation of in vitro assays to assess the inhibition of PD-1‒PD-L1 interactions by full IgG antibodies. The activity of 40 full IgG converted antibodies in blocking the effect of the PD1/PD-L1 checkpoint on TCR-mediated T cell activation is assessed as the level of luciferase activity. MK3475 (anti-PD-1) and MPDL3280A (anti-PD-L1) antibodies were used as positive controls (green bar). The light blue bars have binding activity of antibody clones against human PD-L1 antigen, whereas yellow bars have cross-reactivity to both human and mouse PD-L1 antigens. Results are classified using color shading codes, with the top 30% in red and the bottom 30% in blue in each assay (scFvs 30%; 12/40 clones and 22/72 clones).

    Article Snippet: The human PD-1-Fc (Sino Biological Inc., Beijing, China) proteins were immobilized on the biosensor tip surface.

    Techniques: In Vitro, Inhibition, Activity Assay, Blocking Assay, Activation Assay, Luciferase, Binding Assay, Clone Assay

    Screening of functional scFv antibodies using an optimized BLI-based PD-1/PD-L1-binding inhibition assay. Inhibitory activity analysis of 72 individual periplasmic scFv antibodies. Analysis of inhibitory activity against PD-1‒PD-L1 interaction was performed using BLI-based assays under optimized conditions. The relative inhibitory efficiency of scFvs was calculated by normalizing the PD-1/PD-L1-binding response in the presence of the TES buffer to 100%. Classification and response plots (sensorgrams; for the top four clones of each group) of the three groups by difference in inhibitory efficacy (high, ≥30%; moderate, ≥15%; and low,

    Journal: Viruses

    Article Title: BLI-Based Functional Assay in Phage Display Benefits the Development of a PD-L1-Targeting Therapeutic Antibody

    doi: 10.3390/v12060684

    Figure Lengend Snippet: Screening of functional scFv antibodies using an optimized BLI-based PD-1/PD-L1-binding inhibition assay. Inhibitory activity analysis of 72 individual periplasmic scFv antibodies. Analysis of inhibitory activity against PD-1‒PD-L1 interaction was performed using BLI-based assays under optimized conditions. The relative inhibitory efficiency of scFvs was calculated by normalizing the PD-1/PD-L1-binding response in the presence of the TES buffer to 100%. Classification and response plots (sensorgrams; for the top four clones of each group) of the three groups by difference in inhibitory efficacy (high, ≥30%; moderate, ≥15%; and low,

    Article Snippet: The human PD-1-Fc (Sino Biological Inc., Beijing, China) proteins were immobilized on the biosensor tip surface.

    Techniques: Functional Assay, Binding Assay, Inhibition, Activity Assay, Clone Assay

    The application of the BLI-based assay for epitope characterization of antibodies. ( A ) Classification and assessment of abnormal binding sensorgrams in BLI-based PD-1/PD-L1-binding inhibition assays. In the assay, PD-1 is coated on the sensor and a mixture of PD-L1 and each IgG antibody clone was incubated with the sensor; ( B ) Distribution of #41 (‒144%) and #71 (‒37.63%) clones in BLI-based assays using IgG; ( C ) Binding compatibility test using the BLI assay. The PD-L1-coated sensors were pre-saturated with MPDL3280A antibody binding and two antibodies were introduced to the sensors consecutively to check if any clone has compatible binding with MPDL3280A (tested clones: #3, 6, 10, 24, 26, 29, 35, 40, 41, 50, 51, 52, 56, 63, 70, 71).

    Journal: Viruses

    Article Title: BLI-Based Functional Assay in Phage Display Benefits the Development of a PD-L1-Targeting Therapeutic Antibody

    doi: 10.3390/v12060684

    Figure Lengend Snippet: The application of the BLI-based assay for epitope characterization of antibodies. ( A ) Classification and assessment of abnormal binding sensorgrams in BLI-based PD-1/PD-L1-binding inhibition assays. In the assay, PD-1 is coated on the sensor and a mixture of PD-L1 and each IgG antibody clone was incubated with the sensor; ( B ) Distribution of #41 (‒144%) and #71 (‒37.63%) clones in BLI-based assays using IgG; ( C ) Binding compatibility test using the BLI assay. The PD-L1-coated sensors were pre-saturated with MPDL3280A antibody binding and two antibodies were introduced to the sensors consecutively to check if any clone has compatible binding with MPDL3280A (tested clones: #3, 6, 10, 24, 26, 29, 35, 40, 41, 50, 51, 52, 56, 63, 70, 71).

    Article Snippet: The human PD-1-Fc (Sino Biological Inc., Beijing, China) proteins were immobilized on the biosensor tip surface.

    Techniques: Binding Assay, Inhibition, Incubation, Clone Assay

    Correlation analysis of binding and inhibitory activities of IgG format antibodies. Comparative analysis of binding specificities and in vitro activity according to antibody formats. The vertical axis is the binding and binding inhibition activity in ELISA (circle, 450 nm), flow cytometry (triangle, MFI; mean fluorescence intensity), and BLI-based PD-1/PD-L1 binding inhibition assay (diamond, inhibition %), and the horizontal axis is the PD-1‒PD-L1 interaction inhibitory activity (relative luminescence %) of the antibodies. For the BLI-based PD-1‒PD-L1 binding inhibition assay using IgG, clones #41 (‒144%) and #71 (‒37.63%) are not indicated. Poorly correlated clones are represented by three black boxes. The Pearson correlation coefficient ( r ) and p -value ( p ) are given in the top panel ( r = 0.510, p = 7.66 × 10 −4 ), middle panel ( r = 0.931, p = 3.13 × 10 −18 ), and bottom panel ( r = 0.772, p = 1.14 × 10 −8 ). Results are classified using color shading codes, with the top 30% in red and the bottom 30% in blue (IgGs; 30%; 12/40 clone) in each of the three assays (ELISA, flow cytometry, and BLI-based PD-1/PD-L1-binding inhibition assay).

    Journal: Viruses

    Article Title: BLI-Based Functional Assay in Phage Display Benefits the Development of a PD-L1-Targeting Therapeutic Antibody

    doi: 10.3390/v12060684

    Figure Lengend Snippet: Correlation analysis of binding and inhibitory activities of IgG format antibodies. Comparative analysis of binding specificities and in vitro activity according to antibody formats. The vertical axis is the binding and binding inhibition activity in ELISA (circle, 450 nm), flow cytometry (triangle, MFI; mean fluorescence intensity), and BLI-based PD-1/PD-L1 binding inhibition assay (diamond, inhibition %), and the horizontal axis is the PD-1‒PD-L1 interaction inhibitory activity (relative luminescence %) of the antibodies. For the BLI-based PD-1‒PD-L1 binding inhibition assay using IgG, clones #41 (‒144%) and #71 (‒37.63%) are not indicated. Poorly correlated clones are represented by three black boxes. The Pearson correlation coefficient ( r ) and p -value ( p ) are given in the top panel ( r = 0.510, p = 7.66 × 10 −4 ), middle panel ( r = 0.931, p = 3.13 × 10 −18 ), and bottom panel ( r = 0.772, p = 1.14 × 10 −8 ). Results are classified using color shading codes, with the top 30% in red and the bottom 30% in blue (IgGs; 30%; 12/40 clone) in each of the three assays (ELISA, flow cytometry, and BLI-based PD-1/PD-L1-binding inhibition assay).

    Article Snippet: The human PD-1-Fc (Sino Biological Inc., Beijing, China) proteins were immobilized on the biosensor tip surface.

    Techniques: Binding Assay, In Vitro, Activity Assay, Inhibition, Enzyme-linked Immunosorbent Assay, Flow Cytometry, Fluorescence, Clone Assay

    Illustration of biolayer interferometry (BLI)-based assay and optimization for functional antibody screening. ( A ) The AR2G biosensors were incubated with human PD-1-Fc. The PD-1-Fc immobilized AR2G biosensors were blocked using 3% BSA, followed by incubation with human PD-L1-Fc in the absence or presence of periplasmic scFvs. A binding inhibition signal was detected by BLI, and the inhibition signal intensity of periplasmic scFv antibodies was calculated by normalizing the PD-1/PD-L1 binding signal to 100% in the absence of periplasmic scFv antibodies; ( B ) Optimization of PD-1/PD-L1 protein binding conditions in BLI. The binding capacity and concentration. Assessment of BLI response signal (nm) for human PD-1/PD-L1 protein binding on AR2G chip. Human PD-1 protein was immobilized onto AR2G biosensors via amine coupling.

    Journal: Viruses

    Article Title: BLI-Based Functional Assay in Phage Display Benefits the Development of a PD-L1-Targeting Therapeutic Antibody

    doi: 10.3390/v12060684

    Figure Lengend Snippet: Illustration of biolayer interferometry (BLI)-based assay and optimization for functional antibody screening. ( A ) The AR2G biosensors were incubated with human PD-1-Fc. The PD-1-Fc immobilized AR2G biosensors were blocked using 3% BSA, followed by incubation with human PD-L1-Fc in the absence or presence of periplasmic scFvs. A binding inhibition signal was detected by BLI, and the inhibition signal intensity of periplasmic scFv antibodies was calculated by normalizing the PD-1/PD-L1 binding signal to 100% in the absence of periplasmic scFv antibodies; ( B ) Optimization of PD-1/PD-L1 protein binding conditions in BLI. The binding capacity and concentration. Assessment of BLI response signal (nm) for human PD-1/PD-L1 protein binding on AR2G chip. Human PD-1 protein was immobilized onto AR2G biosensors via amine coupling.

    Article Snippet: The human PD-1-Fc (Sino Biological Inc., Beijing, China) proteins were immobilized on the biosensor tip surface.

    Techniques: Functional Assay, Incubation, Binding Assay, Inhibition, Protein Binding, Concentration Assay, Chromatin Immunoprecipitation

    PD-1 blockade administered prior to ART results in improved viral suppression following ART initiation. Plasma SIV RNA viral loads (copies/ml) shown as ( A ) geometric mean for each group and ( B ) for individual RMs at initiation of anti–PD-1 Ab or saline infusion. Limit of detection is 60 copies/ml. ( C ) Kaplan-Meier curve of number of days until viral suppression (

    Journal: JCI Insight

    Article Title: Combination anti–PD-1 and antiretroviral therapy provides therapeutic benefit against SIV

    doi: 10.1172/jci.insight.122940

    Figure Lengend Snippet: PD-1 blockade administered prior to ART results in improved viral suppression following ART initiation. Plasma SIV RNA viral loads (copies/ml) shown as ( A ) geometric mean for each group and ( B ) for individual RMs at initiation of anti–PD-1 Ab or saline infusion. Limit of detection is 60 copies/ml. ( C ) Kaplan-Meier curve of number of days until viral suppression (

    Article Snippet: To measure the levels of infused PD-1 Ab, plates were coated with human PDCD1/PD-1 protein (Sino Biological, catalog number 10377-H-8H-50) in PBS, blocked, and incubated with different dilutions of plasma to capture the infused anti–PD-1 Ab.

    Techniques:

    PD-1 blockade during suppressive ART (phase II) results in T cell proliferation and potential destabilization of the viral reservoir. ( A ) Ki-67 expression on CD4 + T cells, CD8 + T cells, and GagCM9 + CD8 + T cells in blood after first PD-1 Ab infusion (right: saline, n = 2; single anti–PD-1 treated [ST], n = 3; double anti–PD-1 treated [DT], n = 5). Data are shown as the mean ± SEM. ( B ) Frequency of granzyme B + CD8 + T cells (saline, n = 5; ST, n = 3; DT, n = 10), CXCR5 + GagCM9 + CD8 + T cells (saline, n = 3; ST, n = 2; DT, n = 5), and CXCR5 + CD4 + T cells (saline, n = 5; ST, n = 3; DT, n = 10) in axillary lymph nodes (ALN) at 2 weeks after last PD-1 Ab infusion. Viral outgrowth assay on CD4 + T cells from blood of RMs 2 weeks after the last PD-1 Ab infusion. ( C ) SIV Gag RNA copies/ml assayed from culture supernatant at days 9, 17, and 25 of culture. ( D ) Representative p27 gag staining and ( E ) frequency of p27 gag + CEM cells from day 25 of viral outgrowth assay. For viral outgrowth assay, saline, n = 4; ST, n = 5; DT, n = 8. Unfilled circles indicate values from Mamu-A*01 RMs. Bars indicate the mean. Exact P values are shown. Two-way ANOVA ( A ), 2-tailed Mann-Whitney test ( B and C ), 1-way ANOVA with Dunn’s multiple-comparisons test ( B , right), or 2-tailed Student’s t test ( E ) were used. One saline control animal was interrupted from ART early due to significant weight loss and therefore data are not available for this animal. Unless otherwise noted, saline, n = 4; ST, n = 5; DT, n = 10.

    Journal: JCI Insight

    Article Title: Combination anti–PD-1 and antiretroviral therapy provides therapeutic benefit against SIV

    doi: 10.1172/jci.insight.122940

    Figure Lengend Snippet: PD-1 blockade during suppressive ART (phase II) results in T cell proliferation and potential destabilization of the viral reservoir. ( A ) Ki-67 expression on CD4 + T cells, CD8 + T cells, and GagCM9 + CD8 + T cells in blood after first PD-1 Ab infusion (right: saline, n = 2; single anti–PD-1 treated [ST], n = 3; double anti–PD-1 treated [DT], n = 5). Data are shown as the mean ± SEM. ( B ) Frequency of granzyme B + CD8 + T cells (saline, n = 5; ST, n = 3; DT, n = 10), CXCR5 + GagCM9 + CD8 + T cells (saline, n = 3; ST, n = 2; DT, n = 5), and CXCR5 + CD4 + T cells (saline, n = 5; ST, n = 3; DT, n = 10) in axillary lymph nodes (ALN) at 2 weeks after last PD-1 Ab infusion. Viral outgrowth assay on CD4 + T cells from blood of RMs 2 weeks after the last PD-1 Ab infusion. ( C ) SIV Gag RNA copies/ml assayed from culture supernatant at days 9, 17, and 25 of culture. ( D ) Representative p27 gag staining and ( E ) frequency of p27 gag + CEM cells from day 25 of viral outgrowth assay. For viral outgrowth assay, saline, n = 4; ST, n = 5; DT, n = 8. Unfilled circles indicate values from Mamu-A*01 RMs. Bars indicate the mean. Exact P values are shown. Two-way ANOVA ( A ), 2-tailed Mann-Whitney test ( B and C ), 1-way ANOVA with Dunn’s multiple-comparisons test ( B , right), or 2-tailed Student’s t test ( E ) were used. One saline control animal was interrupted from ART early due to significant weight loss and therefore data are not available for this animal. Unless otherwise noted, saline, n = 4; ST, n = 5; DT, n = 10.

    Article Snippet: To measure the levels of infused PD-1 Ab, plates were coated with human PDCD1/PD-1 protein (Sino Biological, catalog number 10377-H-8H-50) in PBS, blocked, and incubated with different dilutions of plasma to capture the infused anti–PD-1 Ab.

    Techniques: Expressing, Viral Outgrowth Assay, Staining, MANN-WHITNEY

    PD-1 blockade during suppressive ART (phase II) stimulates antiviral cellular response pathways. GSEA of RNA-Seq data from blood at day 7 compared with day 0 following first PD-1 Ab infusion for PD-1 Ab–treated animals during phase II. ( A ) Normalized enrichment scores for upregulated gene sets depicted. Dashed line indicates normalized enrichment score cutoff of greater than 1.35 with a false discovery rate of less than 0.2. ( B ) GSEA plots comparing day 7 (D7) and day 0 (D0) of first PD-1 Ab infusion during phase II. Leading-edge genes from gene sets are shown as black outlined dots. Exact P values are shown. n = 9. ( C ) Leading-edge analysis was performed on positively enriched gene sets that were significant during both phase I and phase II. Genes present in at least 7 gene sets were considered core signature genes. Filled red boxes indicate presence of the gene in the respective gene set.

    Journal: JCI Insight

    Article Title: Combination anti–PD-1 and antiretroviral therapy provides therapeutic benefit against SIV

    doi: 10.1172/jci.insight.122940

    Figure Lengend Snippet: PD-1 blockade during suppressive ART (phase II) stimulates antiviral cellular response pathways. GSEA of RNA-Seq data from blood at day 7 compared with day 0 following first PD-1 Ab infusion for PD-1 Ab–treated animals during phase II. ( A ) Normalized enrichment scores for upregulated gene sets depicted. Dashed line indicates normalized enrichment score cutoff of greater than 1.35 with a false discovery rate of less than 0.2. ( B ) GSEA plots comparing day 7 (D7) and day 0 (D0) of first PD-1 Ab infusion during phase II. Leading-edge genes from gene sets are shown as black outlined dots. Exact P values are shown. n = 9. ( C ) Leading-edge analysis was performed on positively enriched gene sets that were significant during both phase I and phase II. Genes present in at least 7 gene sets were considered core signature genes. Filled red boxes indicate presence of the gene in the respective gene set.

    Article Snippet: To measure the levels of infused PD-1 Ab, plates were coated with human PDCD1/PD-1 protein (Sino Biological, catalog number 10377-H-8H-50) in PBS, blocked, and incubated with different dilutions of plasma to capture the infused anti–PD-1 Ab.

    Techniques: RNA Sequencing Assay

    Enhanced immune responses in PD-1 Ab–treated animals after ART interruption (ATI). ( A ) Frequencies of Ki-67 + (3 weeks after ATI; saline, n = 4), Ki-67 + CXCR5 + (3 weeks after ATI; saline, n = 4), and perforin + (4 weeks after ATI) CD8 + T cells in the blood. ( B ) Frequencies of SIV Gag-specific and Env-specific IFN-γ– and TNF-α–producing CD8 + T cells in the blood at 4 weeks after ATI. Bars indicate the geometric mean. ( C ) Frequency of Tcm CD4 + T cells as percentage of CD3 + T cells in the blood at 2 weeks after ATI (saline, n = 4). ( D ) Frequency of Tregs in the blood at 4 weeks after ATI. ( E ) Ratio of perforin + CD8 + T cells to Tregs at week 4 after ATI. ( F ) Boolean analysis of marker expression of CXCR5, granzyme B, perforin, and Ki-67 on Tem CD8 + T cells at 3 weeks after ATI. Correlations of frequency of granzyme B + CD8 + T cells from lymph nodes (LNs) of animals at day 0 of ATI with ( G ) frequency of perforin + CD8 + T cells at 4 weeks after ATI and ( H ) fold reduction of viral load (VL) from pre-ART set point to week 8 after ATI (single anti–PD-1 treated, n = 3). Unfilled circles indicate values from Mamu-A*01 RMs in A – E . Bars indicate the mean unless otherwise noted. * P

    Journal: JCI Insight

    Article Title: Combination anti–PD-1 and antiretroviral therapy provides therapeutic benefit against SIV

    doi: 10.1172/jci.insight.122940

    Figure Lengend Snippet: Enhanced immune responses in PD-1 Ab–treated animals after ART interruption (ATI). ( A ) Frequencies of Ki-67 + (3 weeks after ATI; saline, n = 4), Ki-67 + CXCR5 + (3 weeks after ATI; saline, n = 4), and perforin + (4 weeks after ATI) CD8 + T cells in the blood. ( B ) Frequencies of SIV Gag-specific and Env-specific IFN-γ– and TNF-α–producing CD8 + T cells in the blood at 4 weeks after ATI. Bars indicate the geometric mean. ( C ) Frequency of Tcm CD4 + T cells as percentage of CD3 + T cells in the blood at 2 weeks after ATI (saline, n = 4). ( D ) Frequency of Tregs in the blood at 4 weeks after ATI. ( E ) Ratio of perforin + CD8 + T cells to Tregs at week 4 after ATI. ( F ) Boolean analysis of marker expression of CXCR5, granzyme B, perforin, and Ki-67 on Tem CD8 + T cells at 3 weeks after ATI. Correlations of frequency of granzyme B + CD8 + T cells from lymph nodes (LNs) of animals at day 0 of ATI with ( G ) frequency of perforin + CD8 + T cells at 4 weeks after ATI and ( H ) fold reduction of viral load (VL) from pre-ART set point to week 8 after ATI (single anti–PD-1 treated, n = 3). Unfilled circles indicate values from Mamu-A*01 RMs in A – E . Bars indicate the mean unless otherwise noted. * P

    Article Snippet: To measure the levels of infused PD-1 Ab, plates were coated with human PDCD1/PD-1 protein (Sino Biological, catalog number 10377-H-8H-50) in PBS, blocked, and incubated with different dilutions of plasma to capture the infused anti–PD-1 Ab.

    Techniques: Marker, Expressing, Transmission Electron Microscopy

    PD-1 blockade administered prior to ART (phase I) results in improved T cell functionality in SIV-infected RMs. ( A ) Schematic of PD-1 blockade strategy during phase I and II. ( B ) Frequency of Ki-67 + CD4 + and Ki-67 + CD8 + T cells in the blood. ( C ) Frequency of SIV Gag-specific and Env-specific IFN-γ– and TNF-α–producing CD4 + and CD8 + T cells in the blood. ( D ) Percentage of Ki-67 + , granzyme B + , and CXCR5 + GagCM9 + CD8 + T cells in the blood (saline, n = 6; PD-1 Ab treated, n = 5). ( E ) Gene set enrichment analysis (GSEA) of RNA-Seq data from blood at day 10 compared with day 0 following PD-1 blockade during phase I (PD-1 Ab treated, n = 10). Normalized enrichment scores for select upregulated and downregulated gene sets depicted. Dashed line indicates normalized enrichment score cutoff of greater than 1.35 for upregulated gene sets and less than –1.35 for downregulated gene sets with a false discovery rate of less than 0.2. ( F ) GSEA plots comparing day 10 (D10) to day 0 (D0) of phase I for PD-1 Ab– and saline-treated ( n = 5) groups. Leading-edge genes from gene sets are shown as black outlined dots. Shaded gray area depicts ART. Unfilled circles indicate values from Mamu-A*01 RMs. Data in B and C are shown as the mean ± SEM. ** P

    Journal: JCI Insight

    Article Title: Combination anti–PD-1 and antiretroviral therapy provides therapeutic benefit against SIV

    doi: 10.1172/jci.insight.122940

    Figure Lengend Snippet: PD-1 blockade administered prior to ART (phase I) results in improved T cell functionality in SIV-infected RMs. ( A ) Schematic of PD-1 blockade strategy during phase I and II. ( B ) Frequency of Ki-67 + CD4 + and Ki-67 + CD8 + T cells in the blood. ( C ) Frequency of SIV Gag-specific and Env-specific IFN-γ– and TNF-α–producing CD4 + and CD8 + T cells in the blood. ( D ) Percentage of Ki-67 + , granzyme B + , and CXCR5 + GagCM9 + CD8 + T cells in the blood (saline, n = 6; PD-1 Ab treated, n = 5). ( E ) Gene set enrichment analysis (GSEA) of RNA-Seq data from blood at day 10 compared with day 0 following PD-1 blockade during phase I (PD-1 Ab treated, n = 10). Normalized enrichment scores for select upregulated and downregulated gene sets depicted. Dashed line indicates normalized enrichment score cutoff of greater than 1.35 for upregulated gene sets and less than –1.35 for downregulated gene sets with a false discovery rate of less than 0.2. ( F ) GSEA plots comparing day 10 (D10) to day 0 (D0) of phase I for PD-1 Ab– and saline-treated ( n = 5) groups. Leading-edge genes from gene sets are shown as black outlined dots. Shaded gray area depicts ART. Unfilled circles indicate values from Mamu-A*01 RMs. Data in B and C are shown as the mean ± SEM. ** P

    Article Snippet: To measure the levels of infused PD-1 Ab, plates were coated with human PDCD1/PD-1 protein (Sino Biological, catalog number 10377-H-8H-50) in PBS, blocked, and incubated with different dilutions of plasma to capture the infused anti–PD-1 Ab.

    Techniques: Infection, RNA Sequencing Assay